Experimental and Molecular Medicine (Mar 2024)

RNA m5C modification upregulates E2F1 expression in a manner dependent on YBX1 phase separation and promotes tumor progression in ovarian cancer

  • Xiaoyi Liu,
  • Qinglv Wei,
  • Chenyue Yang,
  • Hongyan Zhao,
  • Jie Xu,
  • Youchaou Mobet,
  • Qingya Luo,
  • Dan Yang,
  • Xinzhao Zuo,
  • Ningxuan Chen,
  • Yu Yang,
  • Li Li,
  • Wei Wang,
  • Jianhua Yu,
  • Jing Xu,
  • Tao Liu,
  • Ping Yi

DOI
https://doi.org/10.1038/s12276-024-01184-4
Journal volume & issue
Vol. 56, no. 3
pp. 600 – 615

Abstract

Read online

Abstract 5-Methylcytosine (m5C) is a common RNA modification that modulates gene expression at the posttranscriptional level, but the crosstalk between m5C RNA modification and biomolecule condensation, as well as transcription factor-mediated transcriptional regulation, in ovarian cancer, is poorly understood. In this study, we revealed that the RNA methyltransferase NSUN2 facilitates mRNA m5C modification and forms a positive feedback regulatory loop with the transcription factor E2F1 in ovarian cancer. Specifically, NSUN2 promotes m5C modification of E2F1 mRNA and increases its stability, and E2F1 binds to the NSUN2 promoter, subsequently reciprocally activating NSUN2 transcription. The RNA binding protein YBX1 functions as the m5C reader and is involved in NSUN2-mediated E2F1 regulation. m5C modification promotes YBX1 phase separation, which upregulates E2F1 expression. In ovarian cancer, NSUN2 and YBX1 are amplified and upregulated, and higher expression of NSUN2 and YBX1 predicts a worse prognosis for ovarian cancer patients. Moreover, E2F1 transcriptionally regulates the expression of the oncogenes MYBL2 and RAD54L, driving ovarian cancer progression. Thus, our study delineates a NSUN2-E2F1-NSUN2 loop regulated by m5C modification in a manner dependent on YBX1 phase separation, and this previously unidentified pathway could be a promising target for ovarian cancer treatment.